Literature DB >> 12377347

Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center.

Kazufumi Kagawa1, Masao Murakami, Yoshio Hishikawa, Mitsuyuki Abe, Takashi Akagi, Toshihiro Yanou, Go Kagiya, Yoshiya Furusawa, Koichi Ando, Kumie Nojima, Mizuho Aoki, Tatsuaki Kanai.   

Abstract

PURPOSE: To assess the biologic effects of proton and carbon ion beams before clinical use. METHODS AND MATERIALS: Cultured cells from human salivary gland cancer (HSG cells) were irradiated at 5 points along a 190 MeV per nucleon proton and a 320 MeV per nucleon carbon ion beam, with Bragg peaks modulated to 6 cm widths. A linac 4 MV X-ray was used as a reference. Relative biologic effectiveness (RBE) values at each point were calculated from survival curves. Cells were also irradiated in a cell-stack phantom to identify that localized cell deaths were observed at predefined depth. Total body irradiation of C3H/He mice was performed, and the number of regenerating crypts per jejunal section was compared to calculate intestinal RBE values. For carbon ion and referential 4 MV X-ray beams, mouse right legs were irradiated by four-fractional treatment and followed up for skin reaction scoring.
RESULTS: RBE values calculated from cell survival curves at the dose that would reduce cell survival to 10% (D10) ranged from 1.01 to 1.05 for protons and from 1.23 to 2.56 for carbon ions. The cell-stack phantom irradiation revealed localized cell deaths at predefined depth. The intestinal RBE values ranged from 1.01 to 1.08 for protons and from 1.15 to 1.88 for carbon ions. The skin RBE value was 2.16 at C320/6 cm spread-out Bragg peak (SOBP) center.
CONCLUSION: The radiobiologic measurements of proton and carbon ion beams at Hyogo Ion Beam Medical Center are consistent with previous reports using proton beams in clinical settings and carbon ion beams with similar linear energy transfer (LET) values.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377347     DOI: 10.1016/s0360-3016(02)02949-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  36 in total

1.  Reirradiation for recurrent head and neck cancers using charged particle or photon radiotherapy.

Authors:  Hideya Yamazaki; Yusuke Demizu; Tomoaki Okimoto; Mikio Ogita; Kengo Himei; Satoaki Nakamura; Gen Suzuki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka; Ryoongjin Oh
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

2.  Investigation of the relative biological effectiveness and uniform isobiological killing effects of irradiation with a clinical carbon SOBP beam on DNA repair deficient CHO cells.

Authors:  Shigeaki Sunada; Ian M Cartwright; Hirokazu Hirakawa; Akira Fujimori; Mitsuru Uesaka; Takamitsu A Kato
Journal:  Oncol Lett       Date:  2017-04-21       Impact factor: 2.967

Review 3.  Adenoid cystic carcinoma: focus on heavy ion therapy and molecular imaging.

Authors:  Angelo Castello; Laura Olivari; Egesta Lopci
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

4.  The major DNA repair pathway after both proton and carbon-ion radiation is NHEJ, but the HR pathway is more relevant in carbon ions.

Authors:  Ariungerel Gerelchuluun; Eri Manabe; Takaaki Ishikawa; Lue Sun; Kazuya Itoh; Takeji Sakae; Kenshi Suzuki; Ryoichi Hirayama; Aroumougame Asaithamby; David J Chen; Koji Tsuboi
Journal:  Radiat Res       Date:  2015-03-04       Impact factor: 2.841

5.  Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma.

Authors:  M Mima; Y Demizu; D Jin; N Hashimoto; M Takagi; K Terashima; O Fujii; Y Niwa; T Akagi; T Daimon; Y Hishikawa; M Abe; M Murakami; R Sasaki; N Fuwa
Journal:  Br J Radiol       Date:  2013-11-28       Impact factor: 3.039

6.  Particle therapy for mucosal melanoma of the head and neck. A single-institution retrospective comparison of proton and carbon ion therapy.

Authors:  Y Demizu; O Fujii; K Terashima; M Mima; N Hashimoto; Y Niwa; T Akagi; T Daimon; M Murakami; N Fuwa
Journal:  Strahlenther Onkol       Date:  2013-12-22       Impact factor: 3.621

7.  Relative biological effectiveness of the 60-MeV therapeutic proton beam at the Institute of Nuclear Physics (IFJ PAN) in Kraków, Poland.

Authors:  Dorota Słonina; Beata Biesaga; Jan Swakoń; Damian Kabat; Leszek Grzanka; Marta Ptaszkiewicz; Urszula Sowa
Journal:  Radiat Environ Biophys       Date:  2014-07-19       Impact factor: 1.925

8.  Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.

Authors:  Kento Takatori; Kazuki Terashima; Rihito Yoshida; Aya Horai; Shinya Satake; Takayuki Ose; Naoto Kitajima; Yoshikazu Kinoshita; Yusuke Demizu; Nobukazu Fuwa
Journal:  J Gastroenterol       Date:  2013-07-12       Impact factor: 7.527

9.  Simulation study of dosimetric effect in proton beam therapy using concomitant boost technique for unresectable pancreatic cancers.

Authors:  Nobuyoshi Fukumitsu; Toshiyuki Okumura; Yuichi Hiroshima; Toshiki Ishida; Haruko Numajiri; Keiko Nemoto Murofushi; Kayoko Ohnishi; Teruhito Aihara; Hitoshi Ishikawa; Koji Tsuboi; Hideyuki Sakurai
Journal:  Jpn J Radiol       Date:  2018-05-10       Impact factor: 2.374

10.  Comparison of human chordoma cell-kill for 290 MeV/n carbon ions versus 70 MeV protons in vitro.

Authors:  Hiroshi Fujisawa; Paula C Genik; Hisashi Kitamura; Akira Fujimori; Mitsuru Uesaka; Takamitsu A Kato
Journal:  Radiat Oncol       Date:  2013-04-15       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.